Back

External validation of novel bleeding risk scores, ARC-HBR and PRECISE-HBR, in 5116 consecutive ACS patients in clinical practice

29 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Risk and benefits of antithrombotic drugs Antiplatelet Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Aleem Khand

Liverpool University Hospitals NHS Trust, Liverpool (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Non-vitamin K antagonist oral anticoagulants versus warfarin and the risk of cataract in patients with atrial fibrillation: A real-world cohort study
Doctor S. Lin (Hualien, TW)
Abstract Slides
Presentation thumbnail
Prognostic impact of post-procedural low-molecular-weight heparin in high-bleeding risk patients undergoing pci for acute myocardial infarction
Doctor S. Qin (Tianjin, CN)
Abstract Slides
Presentation thumbnail
Impact of recurrent venous thromboembolism and major bleeding events on subsequent mortality in patients with and without active cancer: Insights from the COMMAND VTE Registry-2
Doctor S. Kobayashi (Tsu, JP)
Abstract Slides
Presentation thumbnail
Single versus dual antiplatelet therapy after transcatheter aortic valve implantation in patients without an indication for anticoagulation: a systematic review and meta-analysis
Doctor C. Sanchez Serrano (Ciudad De Mexico, MX)
Abstract Slides
Presentation thumbnail
Concomitant antiplatelet therapy in anticoagulated TAVI patients with atrial fibrillation: impact of sex on bleeding and ischaemic events in ENVISAGE-TAVI AF
Doctor G. Dangas (New York, US)
Abstract Slides

Access the full session

Session thumbnail
Risk and benefits of antithrombotic drugs

The Event

Event poster

ESC Congress 2026

29 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI
29 August 2021
thumbnail
Congress Presentation
Validation of the DOAC Score among patients on vitamin K antagonists
1 September 2025
thumbnail
Congress Presentation
Practical value and external validation of the PRECISE-DAPT cancer score in patients with acute myocardial infarction
31 August 2025
thumbnail
Congress Presentation
Predicting individualized treatment effects of prasugrel vs ticagrelor for acute coronary syndrome: a post hoc analysis of a randomized clinical trial
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources